Hari Krishna Ananthula
Overview
Explore the profile of Hari Krishna Ananthula including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
488
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chawla A, Largajolli A, Hussain A, Kleijn H, Ait-Oudhia S, Anton J, et al.
CPT Pharmacometrics Syst Pharmacol
. 2023 May;
12(8):1107-1118.
PMID: 37147897
Gefapixant, a P2X3-receptor antagonist, demonstrated objective and subjective efficacy in individuals with refractory or unexplained chronic cough. We report a population pharmacokinetic (PopPK) analysis that characterizes gefapixant pharmacokinetics (PKs), quantifies...
2.
Krishna Ananthula H, Parker S, Touchette E, Buller R, Patel G, Kalman D, et al.
BMC Pharmacol Toxicol
. 2018 Dec;
19(1):80.
PMID: 30514402
Background: Several tyrosine kinase inhibitors (TKIs) developed as anti-cancer drugs, also have anti-viral activity due to their ability to disrupt productive replication and dissemination in infected cells. Consequently, such drugs...
3.
Mor V, Rella A, Farnoud A, Singh A, Munshi M, Bryan A, et al.
mBio
. 2018 Mar;
9(2).
PMID: 29535196
No abstract available.
4.
Lazzarini C, Haranahalli K, Rieger R, Krishna Ananthula H, Desai P, Ashbaugh A, et al.
Antimicrob Agents Chemother
. 2018 Mar;
62(5).
PMID: 29507066
The incidence of invasive fungal infections has risen dramatically in recent decades. Current antifungal drugs are either toxic, likely to interact with other drugs, have a narrow spectrum of activity,...
5.
Mor V, Rella A, Farnoud A, Singh A, Munshi M, Bryan A, et al.
mBio
. 2015 Jun;
6(3):e00647.
PMID: 26106079
Unlabelled: Recent estimates suggest that >300 million people are afflicted by serious fungal infections worldwide. Current antifungal drugs are static and toxic and/or have a narrow spectrum of activity. Thus,...
6.
Gaudana R, Krishna Ananthula H, Parenky A, Mitra A
AAPS J
. 2010 May;
12(3):348-60.
PMID: 20437123
Ocular drug delivery has been a major challenge to pharmacologists and drug delivery scientists due to its unique anatomy and physiology. Static barriers (different layers of cornea, sclera, and retina...
7.
Paturi D, Kwatra D, Krishna Ananthula H, Pal D, Mitra A
Int J Pharm
. 2009 Sep;
384(1-2):32-8.
PMID: 19782742
Breast cancer resistance protein (BCRP), a 72 kDa protein belongs to the subfamily G of the human ATP-binding cassette transporter superfamily. Overexpression of BCRP was found to play a major...